Home > Rheumatology > ACR 2019 > Spotlight on Rheumatoid Arthritis > Filgotinib promising in RA patients naïve to methotrexate

Filgotinib promising in RA patients naïve to methotrexate

Presented By
Prof. Rene Westhovens, University of Leuven, Belgium
ACR 2019
Phase 3, FINCH 3
The selective Janus kinase (JAK)1 inhibitor filgotinib induced clinically meaningful responses with high patient rates achieving the study endpoint [1]. Filgotinib, the orally administered, selective inhibitor of JAK1 has shown good efficacy and was well tolerated for the treatment of rheumatoid arthritis (RA) in phase 2 and 3 studies evaluating patients with prior inadequate response to biologics or as add-on to methotrexate [2,3]. The phase 3 FINCH 3 trial, conducted by Prof. Rene Westhovens (University of Leuven, Belgium) and his colleagues, now investigated efficacy and safety of filgotinib as monotherapy or in combination with methotrexate in methotrexate-naïve RA patients. At screening, patients had an ACR functional class 1-3, swollen joint count in 66 joints (SJC66) ≥6, and 68‐joint tender joint count (TJC68) ≥6. A total of 1,249 randomised patients received one of the study drug regimens: group A, filgotinib 200 mg plus methotrexate; group ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on